Oncology Central

ASCO18: Day 1 update


Today at our booth

Today marked the first day of ASCO 2018, here in Chicago. The conference has already been packed with new advancements and data from studies that could significantly impact clinical practice within oncology. Take a look at some of our highlights below, and tell us your thoughts in the comments below.

Remember you can find us at booth #4040, or follow our Twitter updates @OncologyCentral.

Why you should visit booth #4040 tomorrow

Picture of the Day

chicagoWe have arrived in Chicago!

Tomorrow’s key talk to attend


LOXO-292 data (abstract 102) – Saturday 2 June, 8:368:48 in Hall D1

Today’s news

Age-related concerns in cancer patients: geriatric assessment improves doctor-patient communication

Researchers at the University of Rochester (NY, USA) have demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication.

Read the full story here.

Abiraterone for advanced prostate cancer may be more effective for black men than white men

A prospective clinical trial, involving 100 men with metastatic castration-resistant prostate cancer, has demonstrated that black men experience a greater and longer lasting response to the hormone treatment abiraterone (Zytiga®) compared with white men. Furthermore, black men were more likely to have a decline in PSA and had a 5-month longer median time to PSA worsening than white men (16.6 vs. 11.5 months).

Find out further details here.

Study reveals gender disparities in head and neck cancer treatment and outcomes

An analysis from a California hospital system has demonstrated that women with head and neck cancer are less likely to receive intensive chemotherapy and radiation compared to men. Furthermore, the ratio of cancer to non-cancer mortality was 1.92 times higher for women than for men.

Read the full story here.

Prostate cancer survival in black men following chemotherapy may be as good, or better, as in white men

Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.

You can access the full story here.

Best of social media #ASCO18




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.